Brief: An2 Therapeutics And Dndi Collaborate On Clinical Development Of Promising New Oral Compound To Treat Chronic Chagas Disease
23/07/2025 12:21
July 23 (Reuters) - AN2 Therapeutics Inc ANTX.O: AN2 THERAPEUTICS AND DNDI COLLABORATE ON CLINICAL DEVELOPMENT OF PROMISING NEW ORAL COMPOUND TO TREAT CHRONIC CHAGAS DISEASE AN2 THERAPEUTICS INC - EXPECTS PHASE 1 COMPLETION IN 2025 AN2 THERAPEUTICS INC - DNDI TO SHARE CLINICAL TRIAL NETWORK FOR AN2-502998 Source text: ID:nBw5N5b0Va Further company coverage: ANTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AN2 Therapeutics
See all newsBrief: AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(C)(4)
Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
AN2 Therapeutics Q2 net loss widens on higher R&D costs
AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview